Abstract
In August 2009, asenapine (Saphris; Schering–Plough) was approved by the US FDA for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
van Os, J. & Kapur, S. Schizophrenia. Lancet 374, 635–645 (2009).
Belmaker, R. H. Bipolar disorder. N. Engl. J. Med. 351, 476–486 (2004).
Miyamoto, S. et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79–104 (2005).
Meltzer, H. Y., Matsubara, S. & Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 25, 238–246 (1989).
Broekkamp, C. L. et al. Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors. Arzneimittelforschung 40, 544–549 (1990).
De Boer, T. et al. Neurochemical studies with the potential antipsychotic compound trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine maleate. Arzneimittelforschung 40, 550–554 (1990).
Franberg, O. et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology 196, 417–429 (2008).
Food and Drug Administration. FDA labelling information. FDA website [online] (2009).
Shahid, M. et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol. 23, 65–73 (2009).
Potkin, S. G., Cohen, M. & Panagides, J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J. Clin. Psychiatry 68, 1492–1500 (2007).
Meltzer, H. Y. Treatment-resistant schizophrenia — the role of clozapine. Curr. Med. Res. Opin. 14, 1–20 (1997).
Meltzer, H. Y. et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60, 82–91 (2003)
Tiihonen, J. et al. Mortality in schizophrenia: an 11-year follow-up study of the total Finnish population (FIN11 Study). Lancet 374, 620–627 (2009).
Leucht, S. et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 14, 429–447 (2009).
Volpi, S. et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J. Clin. Psychiatry 70, 801–809 (2009).
Lieberman, J. A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209–1223 (2005).
Tiihonen, J. et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333, 224–227 (2006).
IMS MIDAS (IMS Health, 2009).
Arnold, C. et al. Credit Suisse Equity Research Report (Credit Suisse Security, 3 Feb 2009).
Schott, C. et al. JP Morgan North America Equity Research Report (JP Morgan & Chase, 3 Feb 2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
H.Y.M. is a grantee of and a consultant for Lilly, Janssen, Pfizer, Minster, Abbott, Acadia, Dainippon Sumitomo, Azur, Otsuka, Bristol–Myers Squibb and Organon. He is also a consultant for Schering–Plough, Merck, AstraZeneca, Novartis, Biovail and Boehringer Ingelheim.
Rights and permissions
About this article
Cite this article
Meltzer, H., Dritselis, A., Yasothan, U. et al. Asenapine. Nat Rev Drug Discov 8, 843–844 (2009). https://doi.org/10.1038/nrd3027
Issue Date:
DOI: https://doi.org/10.1038/nrd3027
This article is cited by
-
Neue Ansätze in der pharmakologischen Behandlung der Schizophrenie
Psychiatrie und Psychotherapie (2011)